117,055 results match your criteria Ovarian Cancer


[High Expression Level of SP1, CSF1R, and PAK1 Correlates with Sensitivity of Leukemia Cells to the Antibiotic Mithramycin].

Mol Biol (Mosk) 2020 May-Jun;54(3):522-528

Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Moscow, 119991 Russia.

Acute myeloid leukemia (AML) is a genetically heterogeneous group of oncological diseases of the hematopoietic system, which are extremely difficult to treat. The development of new targeted drugs (Hylteritinib, Venetoclax) significantly improved the survival of patients, but resistance, as well as cytotoxic anti-leukemia drugs, often occurs. The search for new molecular targets for the development of effective approaches for the treatment of AML is very urgent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31857/S0026898420030192DOI Listing
January 2020

Claims for compensation from women with cervical cancer in Norway - a retrospective, descriptive study of a 12-year period.

Acta Obstet Gynecol Scand 2020 Jun 3. Epub 2020 Jun 3.

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Introduction: In Norway, all patient-reported claims for compensation are evaluated by The Norwegian System of Patient Injury Compensation (NPE). The number of claims from women with cervical cancer is rising, and the approval rate is high. Our aim was to study claims for compensation from women with cervical cancer in order to identify the type of failures, when in the time-course of treatment medical failures occurred, and the consequences of the failures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.13930DOI Listing

Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.

Dalton Trans 2020 Jun 3. Epub 2020 Jun 3.

Department of Chemistry and Biochemistry, Kent State University, 236 Integrated Sciences Building, Kent, Ohio 44242, USA.

Cisplatin is a platinum-based chemotherapeutic agent widely used in the treatment of various solid tumors. However, a major challenge in the use of cisplatin and in the development of cisplatin derivatives, namely Pt(iv) prodrugs, is their premature reduction in the bloodstream before reaching cancer cells. To circumvent this problem, we designed liposomal nanoparticles coupled with a cholesterol-tethered amphiphilic Pt(iv) prodrug. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/d0dt01297aDOI Listing

Characteristics of early-onset pancreatic cancer and its association with familial pancreatic cancer and hereditary pancreatic cancer syndromes.

Ann Gastroenterol Surg 2020 May 27;4(3):229-233. Epub 2020 Mar 27.

Department of Gastroenterological Surgery Graduate School of Medicine Osaka University Osaka Japan.

The incidence of pancreatic cancer is high among those in their sixties to seventies but low in those in their fifties or younger. Although there is no unified definition regarding the age of early-onset pancreatic cancer, previously published reports suggest that, compared to later-onset pancreatic cancer patients, early-onset pancreatic cancer patients tend to be detected at advanced stages and thus have poor prognoses, but they do not show significantly higher rates of patients with genetic factors. On the other hand, it has been reported that patients with familial pancreatic cancer and hereditary pancreatic cancer syndromes often develop pancreatic cancer at a young age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ags3.12326DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240141PMC

Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic.

Gynecol Oncol Rep 2020 Aug 22;33:100587. Epub 2020 May 22.

University of Virginia Health System, Division of Gynecologic Oncology, United States.

Recent data suggest that BRCA mutation carriers younger than 40 may not benefit from mammography in addition to MRI. Our objective was to evaluate screening modalities utilized in a high-risk population. Clinicopathologic data were abstracted for patients followed in a high risk clinic from 2007 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2020.100587DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256456PMC

Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.

Obstet Gynecol Sci 2020 May 24;63(3):346-356. Epub 2020 Mar 24.

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.

Objective: To investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer.

Methods: PubMed, Embase, and Cochrane Library databases were searched to identify studies that examined the prognostic significance of immunohistochemically assessed PD-L1 expression in histologically confirmed ovarian cancer. Eleven studies on PD-L1 expression involving 1,296 patients with ovarian cancer were included in this meta-analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5468/ogs.2020.63.3.346DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231937PMC

Associations between metabolic syndrome and gynecologic cancer.

Obstet Gynecol Sci 2020 May 31;63(3):215-224. Epub 2020 Mar 31.

Department of Obstetrics and Gynecology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.

Metabolic syndrome (MetS) is a group of risk factors that causes cardiovascular and diabetic morbidity and mortality, which is diagnosed by central obesity, dyslipidemia, hyperglycemia, and hypertension. Increasing epidemiological data and experimental results indicate that the presence of MetS increases the incidence of common malignancies and related mortality. Epidemiological studies have previously reported an association of endometrial cancer occurrence with MetS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5468/ogs.2020.63.3.215DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231948PMC

Prognostic Factors among Brain Metastases in Newly Diagnosed Ovary Cancer: A Large Real-world Study.

J Cancer 2020 18;11(15):4625-4640. Epub 2020 May 18.

The Reproductive Medical Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China.

: Population-based data on the prognosis of brain metastases at initial diagnosis of ovary cancer (OCBM) are currently lacking. Besides, the effective treatment for OCBM patients is still controversial now. The study aimed to explore the prognostic factors among OCBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.44494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255353PMC

LPS and IL-8 activated umbilical cord blood-derived neutrophils inhibit the progression of ovarian cancer.

J Cancer 2020 18;11(15):4413-4420. Epub 2020 May 18.

Department of Obstetrics and Gynecology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.

: Immunotherapy including immune checkpoint blockade, cancer vaccines, and adoptive cell therapy. However, no immune therapies support ovarian cancer. It is not clear whether the neutrophils, the component of the immune system derived from umbilical cord blood play a role in inhibiting the progression of ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.41035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255365PMC

Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells.

Dose Response 2020 Apr-Jun;18(2):1559325820926732. Epub 2020 May 19.

Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, China.

Garcinol is a plant-derived compound that has some physiological benefits to human cells. However, the effect of garcinol on ovarian cancer (OC) cell proliferation and apoptosis is unknown. The current study aimed to examine the effects of garcinol alone and in combination with cisplatin (DDP) on cellular behavior and to explore the expression pattern of PI3K/AKT and nuclear factor-κB (NF-κB) in human OC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1559325820926732DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238453PMC

Early diagnosis of breast and ovarian cancers by body fluids circulating tumor-derived exosomes.

Cancer Cell Int 2020 24;20:187. Epub 2020 May 24.

Department of Pathology, School of Veterinary Medicine, Shahrekord University, Shahrekord, Iran.

Exosomes (EXs) are small extracellular vesicles, a size range of 40-100 nm in diameter, actively secreted by most eukaryotic cells into surrounding body fluids like blood, saliva, urine, bile, breast milk and etc. These endosomal-derived vesicles mediate cell-cell communication between various cell populations through transmitting different signaling molecules such as lipids, proteins, and nucleic acids, and participate in a wide range of physiological and pathological body processes. Tumor-derived EXs (TDEs) are vehicles for intercellular communications by transferring bioactive molecules; they deliver oncogenic molecules and contain different molecular cargoes compared to EXs delivered from normal cells, therefore, they can be used as non-invasive invaluable biomarkers for early diagnosis and prognosis of most cancers, including breast and ovarian cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-020-01276-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247259PMC

LncRNA MEG3 suppressed the progression of ovarian cancer via sponging miR-30e-3p and regulating LAMA4 expression.

Cancer Cell Int 2020 24;20:181. Epub 2020 May 24.

Key Laboratory of Birth Defect Prevention of National Health Commission, Zhengzhou, 450002 Henan China.

Background: Ovarian cancer (OC) is a common female reproductive malignancy with a high mortality rate. Although LAMA4 was observed to be downregulated in OC cells, its mechanism in regulating OC metastasis is still unknown. This study aimed to investigate the effect of LAMA4 and its mechanism on OC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-020-01259-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245736PMC

Prognostic Significance of the MAD1L1 1673 G: A Polymorphism in Ovarian Adenocarcinomas.

Rev Invest Clin 2020 May 7;73(3). Epub 2020 May 7.

Cancer Biomedical Research Unit, Instituto Nacional de Cancerología, SSA-Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM); Instituto Nacional de Medicina Genómica; Mexico City, Mexico.

Background: Ovarian cancer is the most lethal gynecologic cancer. Although most patients respond adequately to the first-line therapy, up to 85% experience a recurrence of disease, which carries a poor prognosis. Mitotic arrest deficiency 1 is a protein that helps in the assembly of the mitotic spindle assembly checkpoint by preventing anaphase until all chromatids are properly aligned. Read More

View Article

Download full-text PDF

Source

Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.

Int J Gynecol Cancer 2020 Jun 2. Epub 2020 Jun 2.

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Objectives: Ovarian cancer patients with miliary disease have the lowest rates of complete surgical resection and poorest survival. Adjunct surgical techniques may potentially increase rates of complete surgical resection. No studies have evaluated the use of these techniques in primary debulking surgery for ovarian cancer patients with miliary disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001466DOI Listing

Differential blood count as triage tool in evaluation of pelvic masses.

Int J Gynecol Cancer 2020 Jun 2. Epub 2020 Jun 2.

Dana Farber Cancer Institute, Boston, Massachusetts, USA.

Objective: Triaging patients with presumptive ovarian cancer to the appropriate specialist may improve survival. Therefore, there is increasing interest in complementary diagnostic markers to the standard serum CA125. In patients with pelvic masses, we examined the ability of epidemiologic variables and preoperative differential blood counts to improve detection of ovarian cancer over CA125 alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2019-001103DOI Listing

Diagnostic Reliability, Accuracy and Safety of Ultrasound-guided Biopsy and Ascites Puncture in Primarily Inoperable Ovarian Tumours.

Anticancer Res 2020 Jun;40(6):3527-3534

Department of Gynecology and Obstetrics, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic

Background/aim: To compare the diagnostic reliability, accuracy and safety of ultrasound-guided biopsy (Tru-Cut biopsy) and ascites puncture in patients with a primarily inoperable malignant ovarian tumor.

Patients And Methods: This is a retrospective analysis of the studied methods in consecutively examined patients and a prospective validation of these methods. 79 women with a suspected primarily inoperable ovarian tumor underwent Tru-Cut biopsies and were included in the ultrasound-guided biopsy group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14341DOI Listing

Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells .

Anticancer Res 2020 Jun;40(6):3129-3138

TAYS Cancer Centre and Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Background/aim: The combination of paclitaxel and carboplatin is the standard chemotherapy for ovarian cancer. Previous studies have implied that vitamin D (1,25-D3) may have growth inhibitory effects in ovarian cancer. This study aimed to investigate the effect of paclitaxel, carboplatin and 1,25-D3 on the growth of ovarian cancer cells in vitro, based on the hypothesis that 1,25-D3 might potentiate the effect of paclitaxel and/or carboplatin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14294DOI Listing

PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review.

Anticancer Res 2020 Jun;40(6):3055-3063

Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil

The idea of utilizing poly-ADP-ribose polymerase inhibitors (PARPi) as therapeutics for cancer has grown in popularity since its original approval for clinical usage in treatment of BRCA DNA repair-associated-mutated ovarian cancer. In this study, we evaluated experimental data regarding in vitro studies utilizing PARPi as a treatment for tyrosine kinase (TK)-dependent leukemia. Studies from 2015 to 2019 were compiled and the ones with most relevant TK pathways and PARP inhibition were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14286DOI Listing

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.

J Transl Med 2020 Jun 1;18(1):220. Epub 2020 Jun 1.

The First Department of Oncologic Gynecology and Gynecology, Medical University of Lublin, 20-081, Lublin, Poland.

Background: Previous studies have shown clinical relevance of programmed death-ligand 1 (PD-L1) and soluble PD-L1 (sPD-L1) in human cancers. However, still contradictory results exist. Our aim was evaluation of PD-L1-expressing monocytic myeloid-derived suppressor cells (M-MDSCs), monocytes/macrophages (MO/MA), tumour cells (TC) and immune/inflammatory cells (IC) as well as investigation of the sPD-L1 in ovarian cancer (OC) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-020-02389-7DOI Listing

An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.

Expert Opin Pharmacother 2020 Jun 3:1-14. Epub 2020 Jun 3.

Department of Surgical Oncology, Medical School of Crete University Hospital , Heraklion, Greece.

Introduction: Despite, the strong rationale and evidence of the benefit of postoperative intraperitoneal chemotherapy in advanced ovarian cancer, it has not been widely adopted, mainly due to its high morbidity and logistical difficulties. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is a more tolerable and technically feasible method of intraperitoneal chemotherapy, whereas other potential advantages include homogenous drug distribution, application before tumor regrowth and combination with hyperthermia, which is directly cytotoxic and enhances the efficacy of many drugs.

Areas Covered: In this review, the authors explain the rationale and indications for cytoreductive surgery (CRS) and HIPEC in advanced ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2020.1766024DOI Listing

[Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].

Zhonghua Bing Li Xue Za Zhi 2020 Jun;49(6):588-593

Department of Pathology, the First Medical Center of PLA General Hospital, Beijing 100853, China.

To investigate the clinical, pathological and immunohistochemical features of seromucinous neoplasms, including seromucinous cystadenoma, borderline tumour and seromucinous carcinomas of the ovary. A retrospective review of the seromucinous neoplasms collected between June 2006 and December 2018 was conducted at the First Medical Center of PLA General Hospital. EnVision immunohistochemical staining was used to detect the expression of CK7, PAX8, ER, PR, WT1, p16, p53 and Baf250a which was encoded by the ARID1A gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112151-20200224-00130DOI Listing

Galectins and Ovarian Cancer.

Cancers (Basel) 2020 May 31;12(6). Epub 2020 May 31.

Department of Obstetrics and Gynecology, Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA 02114, USA.

Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features. Galectins, a family of glycan-binding proteins defined by a conserved carbohydrate recognition domain, can modulate many of these processes, enabling them to contribute to the pathology of ovarian cancer. Our goal herein was to review specific galectin members identified in the context of ovarian cancer, with emphasis on their association with clinical and pathological features, implied functions, diagnostic or prognostic potential and strategies being developed to disrupt their negative actions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061421DOI Listing

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.

Int J Mol Sci 2020 May 29;21(11). Epub 2020 May 29.

Genome Analysis Center, Yamanashi Central Hospital, Kofu 400-8506, Japan.

variants are prognostic biomarkers for hereditary breast and/or ovarian cancer (HBOC) syndrome and predictive biomarkers for PARP inhibition. In this study, we benchmarked the classification of variants from patients with HBOC-related cancer using MH BRCA, a novel computational technology that combines the ACMG guidelines with expert-curated variant annotations. Evaluation of variants ( = 1040) taken from four HBOC studies showed strong concordance within the pathogenic (98. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21113895DOI Listing

Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review.

Cancers (Basel) 2020 May 29;12(6). Epub 2020 May 29.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77033, USA.

Non-epithelial ovarian tumors are heterogeneous and account for approximately 10% of ovarian malignancies. The most common subtypes of non-epithelial ovarian tumors arise from germ cells or sex cord and stromal cells of the gonads. These tumors are usually detected at an early stage, and management includes surgical staging and debulking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061398DOI Listing

Using machine learning to predict ovarian cancer.

Int J Med Inform 2020 May 23;141:104195. Epub 2020 May 23.

Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, People's Republic of China; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, People's Republic of China; Institute of Cell Therapy, Soochow University, Changzhou, Jiangsu, People's Republic of China. Electronic address:

Objective: Ovarian cancer (OC) is one of the most common types of cancer in women. Accurately prediction of benign ovarian tumors (BOT) and OC has important practical value.

Methods: Our dataset consists of 349 Chinese patients with 49 variables including demographics, blood routine test, general chemistry, and tumor markers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijmedinf.2020.104195DOI Listing

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.

Cancer Treat Rev 2020 May 26;87:102040. Epub 2020 May 26.

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Gynaecology, European Competence Center for Ovarian Cancer, Campus Virchow Clinic, 13353 Berlin, Germany.

Background: The second decade of 2000s is witnessing a new ovarian cancer (OC) paradigm shift thanks to the results recently obtained by a new class of targeted agents: the Poly(ADP-ribose)polymerase (PARP)-Inhibitors (PARPi). Aim of this meta-analysis is to analyze available results obtained with PARPi, administered alone or in combination with chemo- and/or target-therapies in terms of efficacy and safety for the treatment of recurrent and primary advanced OC.

Methods: On December 2019, all published phase II/III randomized clinical studies were systematically searched using the terms "[Parp-Inhibitor] AND [ovar*]". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102040DOI Listing

Novel aspects on gonadotoxicity and fertility preservation in lymphoproliferative neoplasms.

Crit Rev Oncol Hematol 2020 May 15;151:102981. Epub 2020 May 15.

Haematology Unit, National Cancer Center, IRCCS Istituto Tumori "Giovanni Paolo II", viale O. Flacco 65, Bari, Italy. Electronic address:

The topic of fertility preservation in patients with a lymphoproliferative disease offers new aspects of debate, due to the introduction of novel chemotherapeutic regimens and small molecules in the clinical landscape. Cancer related infertility is mostly dependent on gonadotoxic treatments and fertile female patients are today addressed to the oocyte cryopreservation or to ovarian cortex fragment cryopreservation. These methods present advantages and disadvantages, which will be discussed in the present review, together with the options for male patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2020.102981DOI Listing

Spontaneous arterial thrombosis in a patient with advanced ovarian clear cell cancer: a case report and literature review.

J Int Med Res 2020 Jun;48(6):300060520926742

Department of Gynecology & Obstetrics, Zhongshan Hospital, Fudan University, Shanghai, China.

Patients with ovarian cancer are often in a hypercoagulable state and have a high risk of venous thrombosis, including deep vein thrombosis and pulmonary embolism. However, arterial thrombosis is relatively rare in ovarian cancer. We report a case a 46-year-old woman with ovarian clear cell carcinoma who developed arterial and venous thrombosis in the lower extremities as the first manifestation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300060520926742DOI Listing

Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.

Cancer 2020 Jun 2. Epub 2020 Jun 2.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Background: Poor outcomes for patients with ovarian cancer relate to dormant, drug-resistant cancer cells that survive after primary surgery and chemotherapy. Ovarian cancer (OvCa) cells persist in poorly vascularized scars on the peritoneal surface and depend on autophagy to survive nutrient deprivation. The authors have sought drugs that target autophagic cancer cells selectively to eliminate residual disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32985DOI Listing

Residential segregation and overall survival of women with epithelial ovarian cancer.

Cancer 2020 Jun 2. Epub 2020 Jun 2.

Department of Public Health Sciences, University of Miami Leonard M. Miller School of Medicine, Miami, Florida, USA.

Background: To the authors' knowledge, the etiology of survival disparities in patients with epithelial ovarian cancer (EOC) is not fully understood. Residential segregation, both economic and racial, remains a problem within the United States. The objective of the current study was to analyze the effect of residential segregation as measured by the Index of Concentration at the Extremes (ICE) on EOC survival in Florida by race and/or ethnicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32989DOI Listing

MGAT3-mediated glycosylation of tetraspanin CD82 at asparagine 157 suppresses ovarian cancer metastasis by inhibiting the integrin signaling pathway.

Theranostics 2020 16;10(14):6467-6482. Epub 2020 May 16.

State Key Laboratory of Medicinal Chemical Biology, School of Medicine, Nankai University, Tianjin, China.

: Tetraspanins constitute a family of transmembrane spanning proteins that function mainly by organizing the plasma membrane into micro-domains. CD82, a member of tetraspanins, is a potent inhibitor of cancer metastasis in numerous malignancies. CD82 is a highly glycosylated protein, however, it is still unknown whether and how this post-translational modification affects CD82 function and cancer metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.43865DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255015PMC

Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10.

Theranostics 2020 27;10(13):5895-5913. Epub 2020 Apr 27.

Department of Pathology, Xiangya Hospital, School of Basic Medical Sciences, Central South University, Changsha, Hunan Province, China.

: Epithelial ovarian cancer (EOC) is one of the most lethal malignancies in women worldwide. Many studies showed the transcription factor SNAI2-induced Epithelial-Mesenchymal Transition (EMT) through inhibiting E-cadherin (E-cad) expression. Our previous study reported that miR-222-3p was an important tumor-suppressive miRNA for EOC development and dissemination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.43198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254989PMC

Ubiquitin ligase CHIP regulates OTUD3 stability and suppresses tumour metastasis in lung cancer.

Cell Death Differ 2020 Jun 1. Epub 2020 Jun 1.

State Key Laboratory of Proteomics, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, 100850, Beijing, China.

Ovarian tumour domain-containing protein 3 (OTUD3), a key OTU (ovarian tumour protease) family deubiquitylase, plays context-dependent roles in cancers. It suppresses tumorigenesis in breast, colon, liver and cervical cancer through stabilizing PTEN (phosphatase and tension homologue deleted on chromosome 10) while promotes lung tumorigenesis through stabilizing GRP78 (The glucose-regulated protein 78 kDa). The regulation especially post-translational modification of OTUD3 remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41418-020-0571-7DOI Listing

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.

Nat Med 2020 Jun 1. Epub 2020 Jun 1.

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

An increasing fraction of patients with metastatic cancer develop leptomeningeal dissemination of disease (LMD), and survival is dismal. We conducted a single-arm, phase 2 study of pembrolizumab in patients with solid tumor malignancies and LMD (NCT02886585). Patients received 200 mg of pembrolizumab intravenously every 3 weeks until definitive progression or unacceptable toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-020-0918-0DOI Listing

Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.

Nat Genet 2020 Jun 1. Epub 2020 Jun 1.

Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.

In metastatic cancer, the degree of heterogeneity of the tumor microenvironment (TME) and its molecular underpinnings remain largely unstudied. To characterize the tumor-immune interface at baseline and during neoadjuvant chemotherapy (NACT) in high-grade serous ovarian cancer (HGSOC), we performed immunogenomic analysis of treatment-naive and paired samples from before and after treatment with chemotherapy. In treatment-naive HGSOC, we found that immune-cell-excluded and inflammatory microenvironments coexist within the same individuals and within the same tumor sites, indicating ubiquitous variability in immune cell infiltration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41588-020-0630-5DOI Listing

Ovarian cancer risk in relation to blood lipid levels and hyperlipidemia: a systematic review and meta-analysis of observational epidemiologic studies.

Eur J Cancer Prev 2020 May 29. Epub 2020 May 29.

University of Michigan Medical School, Ann Arbor, Michigan, USA.

Epidemiologic evidence regarding association of ovarian cancer risk with blood lipid level and hyperlipidemia is inconsistent. We aimed to synthesize available epidemiologic studies to disentangle associations of cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and hyperlipidemia with ovarian cancer risk. We searched PubMed, EMBASE, and Web of Science for eligible studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CEJ.0000000000000597DOI Listing

Preservation of fertility in premenopausal patients with breast cancer.

Hong Kong Med J 2020 May 28. Epub 2020 May 28.

Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.

Introduction: Cancer survivorship is increasingly important with advances in cancer therapeutics. Minimisation of treatment-related morbidity is an area that requires attention. This situation is most pressing in premenopausal patients with breast cancer, in whom advances in hormonal and targeted therapies have improved mortality rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12809/hkmj198268DOI Listing

Homozygous hypomorphic variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait.

J Med Genet 2020 Jun 1. Epub 2020 Jun 1.

Faculte de Medecine, Universite Paris Saclay, Hopital Bicêtre APHP, Le Kremlin-Bicetre, France

Background: Primary ovarian insufficiency (POI) affects 1% of women under 40 years and is a public health problem. The genetic causes of POI are highly heterogeneous with isolated or syndromic forms. Recently, variants in genes involved in DNA repair have been shown to cause POI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jmedgenet-2019-106672DOI Listing

Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk-Response.

Cancer Epidemiol Biomarkers Prev 2020 Jun;29(6):1279

Moffitt Cancer Center, Tampa, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-19-1388DOI Listing

Copy Number Variation and Ovarian Cancer Risk-Letter.

Cancer Epidemiol Biomarkers Prev 2020 Jun;29(6):1278

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-19-0944DOI Listing

Adjusting to the new reality: Evaluation of early practice pattern adaptations to the COVID-19 pandemic.

Gynecol Oncol 2020 May 23. Epub 2020 May 23.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Penn State Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA.

Objective: We aim to define national practice patterns to assess current clinical practice, anticipated delays and areas of concern that potentially could lead to deviations from the normal standard of care.

Methods: Anonymous surveys were emailed to members of the Society of Gynecologic Oncology (SGO). The spread of COVID-19 and its impact on gynecologic oncology care in terms of alterations to normal treatment patterns and anticipated challenges were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.05.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245245PMC

PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.

Blood Rev 2020 May 7:100696. Epub 2020 May 7.

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14263, USA. Electronic address:

Poly (ADP-ribose) polymerase (PARP) inhibitors, which induce synthetic lethality of BRCA mutant breast and ovarian cancers, are now under active exploration for treatment of acute leukemias, specifically acute myeloid leukemia (AML). Experimental data has revealed that DNA repair deficiencies similar to those found in BRCA mutant solid tumors function in malignant hematopoietic cells to enhance cell survival and promote therapy resistance. Preclinical studies have demonstrated that inhibition of PARP with a variety of agents can dramatically enhance the efficacy of other therapeutic approaches including cytotoxic and epigenetic chemotherapy, small molecule inhibitors (IDH and FLT3 inhibitors) and antibody drug conjugates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2020.100696DOI Listing

Incorporation of arginine, glutamine or leucine in culture medium accelerates activation of primordial follicles in 1-day-old mouse ovary.

Zygote 2020 Jun 2:1-8. Epub 2020 Jun 2.

Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.

In vitro activation of primordial follicles provides cancer patients subjected to oncotherapy with a safe therapeutic strategy for fertility preservation, however a successful protocol for activation of primordial follicles in prepubertal patients has not yet been defined comprehensively. There is evidence that amino acids such as leucine, arginine and glutamine could stimulate the mammalian target of rapamycin (mTOR) pathway, which plays a pivotal role in primordial follicle activation. Nevertheless, there has been no report that elucidates the effect of these amino acids on in vitro development of ovarian follicles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S096719942000026XDOI Listing

The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells.

Drug Dev Ind Pharm 2020 Jun 2:1-36. Epub 2020 Jun 2.

Shanghai First Maternity and Infant Hospital, Tong Ji University School of Medicine, Shanghai 201204, China.

Objective: To assess the feasibility of an exosome-based drug delivery platform for the potent chemotherapeutic agent cisplatin to treat ovarian cancer.

Significance: Exosomes have recently been used as drug delivery vehicles because of their natural advantages. Platinum-resistant forms of ovarian cancer require novel drug delivery methods to improve patient outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03639045.2020.1776320DOI Listing

in Breast and Ovarian Cancers.

Int J Mol Sci 2020 May 28;21(11). Epub 2020 May 28.

Department of Medical Biology and Pathology, Gustave Roussy, Cancer Genetics Laboratory, Gustave Roussy, 94800 Villejuif, France.

Ovarian and breast cancers are currently defined by the main pathways involved in the tumorigenesis. The majority are carcinomas, originating from epithelial cells that are in constant division and subjected to cyclical variations of the estrogen stimulus during the female hormonal cycle, therefore being vulnerable to DNA damage. A portion of breast and ovarian carcinomas arises in the context of DNA repair defects, in which genetic instability is the backdrop for cancer initiation and progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21113850DOI Listing

Role of Collagen Fiber Morphology on Ovarian Cancer Cell Migration Using Image-Based Models of the Extracellular Matrix.

Cancers (Basel) 2020 May 28;12(6). Epub 2020 May 28.

Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA.

Remodeling of the extracellular matrix (ECM) is an important part in the development and progression of many epithelial cancers. However, the biological significance of collagen alterations in ovarian cancer has not been well established. Here we investigated the role of collagen fiber morphology on cancer cell migration using tissue engineered scaffolds based on high-resolution Second-Harmonic Generation (SHG) images of ovarian tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061390DOI Listing

Stigmasterol Causes Ovarian Cancer Cell Apoptosis by Inducing Endoplasmic Reticulum and Mitochondrial Dysfunction.

Pharmaceutics 2020 May 28;12(6). Epub 2020 May 28.

Department of Food and Nutrition, College of Science and Technology, Kookmin University, Seoul 02707, Korea.

Background: Phytosterols have physiological effects and are used as medicines or food supplements. Stigmasterol has shown anticancer effects against various cancers such as hepatoma, cholangiocarcinoma, gall bladder carcinoma, endometrial adenocarcinoma and skin, gastric, breast, prostate, and cervical cancer. However, there are no reports on stigmasterol's effects on ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/pharmaceutics12060488DOI Listing

Effect of shikonin on the proliferation and apoptosis of human ovarian cancer cell SKOV3: A protocol of systematic review and meta-analysis.

Medicine (Baltimore) 2020 May;99(22):e20450

Department of Chemotherapy and Radiotherapy, First Affiliated Hospital of Jiamusi University.

Background: This study will investigate the effect of shikonin on the proliferation and apoptosis of human ovarian cancer cell SKOV3 (HOCC-SKOV3).

Methods: We will retrieve potential studies from inception to the March 1, 2020 in Cochrane Library, MEDLINE, EMBASE, Scopus, Cumulative Index to Nursing and Allied Health Literature, WANGFANG, and China National Knowledge In-frastructure. There are not restrictions related to the language and publication status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020450DOI Listing

Contribution of xeroderma pigmentosum complementation group D gene polymorphisms in breast and ovarian cancer susceptibility: A protocol for systematic review and meta analysis.

Medicine (Baltimore) 2020 May;99(21):e20299

Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, P R China.

Background: The role of xeroderma pigmentosum complementation group D (XPD) gene polymorphisms in breast and ovarian cancer development has long been controversial and existing data were inconsistent. Here, we conducted a comprehensive systemic review and meta-analysis to better clarify the association.

Methods: Relevant case-control studies published in electronic data base from October 1999 to September 2019 were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020299DOI Listing